Jessie Gu

961 total citations
17 papers, 724 citations indexed

About

Jessie Gu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jessie Gu has authored 17 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jessie Gu's work include Lung Cancer Research Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Drug Transport and Resistance Mechanisms (3 papers). Jessie Gu is often cited by papers focused on Lung Cancer Research Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Drug Transport and Resistance Mechanisms (3 papers). Jessie Gu collaborates with scholars based in United States, Switzerland and Japan. Jessie Gu's co-authors include R. Sarangapani, Monica Ligueros‐Saylan, Dean F. Rigel, Tsu‐Han Lin, Priya Chandra, William P. Dole, Adele Noè, Gary M. Ksander, Suliman Al‐Fayoumi and Arco Y. Jeng and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

Jessie Gu

17 papers receiving 714 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jessie Gu United States 9 363 192 187 147 90 17 724
Michiel P. de Boer Netherlands 11 226 0.6× 120 0.6× 127 0.7× 215 1.5× 73 0.8× 14 770
Ikuko Nakamura Japan 10 222 0.6× 140 0.7× 64 0.3× 210 1.4× 241 2.7× 19 699
Matthew J. Lovell United Kingdom 14 263 0.7× 109 0.6× 157 0.8× 245 1.7× 23 0.3× 21 871
Suguru Shirotake Japan 20 106 0.3× 431 2.2× 406 2.2× 209 1.4× 81 0.9× 89 1.1k
Tao Jin China 10 103 0.3× 265 1.4× 85 0.5× 212 1.4× 87 1.0× 26 595
Joseph Pierre Aboumsallem Netherlands 15 336 0.9× 49 0.3× 109 0.6× 135 0.9× 59 0.7× 36 570
Peter Groves United Kingdom 14 410 1.1× 121 0.6× 40 0.2× 140 1.0× 66 0.7× 22 812
Nerea Hermida Spain 11 391 1.1× 73 0.4× 71 0.4× 351 2.4× 55 0.6× 17 804
Luigi Cavuto Italy 14 413 1.1× 116 0.6× 38 0.2× 268 1.8× 144 1.6× 14 902
Tadashi Kuroda Japan 13 489 1.3× 123 0.6× 51 0.3× 304 2.1× 195 2.2× 18 956

Countries citing papers authored by Jessie Gu

Since Specialization
Citations

This map shows the geographic impact of Jessie Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessie Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessie Gu more than expected).

Fields of papers citing papers by Jessie Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessie Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessie Gu. The network helps show where Jessie Gu may publish in the future.

Co-authorship network of co-authors of Jessie Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Jessie Gu. A scholar is included among the top collaborators of Jessie Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessie Gu. Jessie Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Goto, Yasushi, Wu‐Chou Su, Benjamin Levy, et al.. (2023). TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9004–9004. 39 indexed citations
2.
Chen, Jin, Rowan Stringer, Jessie Gu, et al.. (2022). Drug‐Drug Interaction Studies to Evaluate the Effect of Inhibition of UGT1A1 and CYP3A4 and Induction of CYP3A4 on the Pharmacokinetics of Tropifexor in Healthy Subjects. Clinical Pharmacology in Drug Development. 11(11). 1253–1263. 3 indexed citations
3.
Shimizu, Toshio, Aaron Lisberg, Jacob Sands, et al.. (2021). O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*. Annals of Oncology. 32. S285–S285. 6 indexed citations
4.
Miao, Zhuang, Lai Wang, Helen Gu, et al.. (2021). Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism. Drug Metabolism and Disposition. 49(7). 548–562. 3 indexed citations
5.
6.
Chen, Jin, Jessie Gu, Rowan Stringer, et al.. (2021). Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment. The Journal of Clinical Pharmacology. 62(4). 520–531. 1 indexed citations
7.
Meric‐Bernstam, Funda, Alexander I. Spira, Aaron Lisberg, et al.. (2021). TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). 9058–9058. 25 indexed citations
8.
Westin, Jason R., Michael Bishop, Ian W. Flinn, et al.. (2019). BELINDA: A Phase 3 Study Evaluating the Safety and Efficacy of Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 19. S270–S271. 3 indexed citations
9.
Dziadziuszko, Rafał, Dong‐Wan Kim, Alessandra Bearz, et al.. (2017). P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC. Journal of Thoracic Oncology. 12(1). S1184–S1184. 5 indexed citations
10.
Dobrenkov, Konstantin, Irina Ostrovnaya, Jessie Gu, Irene Y. Cheung, & Nai‐Kong V. Cheung. (2016). Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatric Blood & Cancer. 63(10). 1780–1785. 104 indexed citations
11.
12.
Spurgeon, Stephen E., Nina D. Wagner‐Johnston, Richard R. Furman, et al.. (2013). Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).. Journal of Clinical Oncology. 31(15_suppl). 8519–8519. 14 indexed citations
13.
Pepe, Margaret S., Jessie Gu, & Daryl E. Morris. (2010). The Potential of Genes and Other Markers to Inform about Risk. Cancer Epidemiology Biomarkers & Prevention. 19(3). 655–665. 32 indexed citations
14.
Ray, Chad, Lei Zhou, Jennifer Tsoi, et al.. (2010). A strategy for improving comparability across sites for ligand binding assays measuring therapeutic proteins. Journal of Pharmaceutical and Biomedical Analysis. 53(3). 729–734. 8 indexed citations
15.
Gu, Jessie, Adele Noè, Priya Chandra, et al.. (2009). Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi). The Journal of Clinical Pharmacology. 50(4). 401–414. 406 indexed citations
16.
Wang, Kenneth K., Kevin C. Halling, Mark A. Nelson, et al.. (2009). 1035 The Use of FISH in a Multi-Center Blinded Study to Predict Development of Neoplasia in Barrett's Esophagus. Gastroenterology. 136(5). A–157. 1 indexed citations
17.
Clark, Jarrod, Jessie Gu, Kevin Chan, et al.. (2008). Performance of a Single Assay for Both Type III and Type VI TMPRSS2:ERG Fusions in Noninvasive Prediction of Prostate Biopsy Outcome. Clinical Chemistry. 54(12). 2007–2017. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michiel P. de Boer Breakdown of academic impact, for papers by Ikuko Nakamura Breakdown of academic impact, for papers by Matthew J. Lovell Breakdown of academic impact, for papers by Suguru Shirotake Breakdown of academic impact, for papers by Tao Jin Breakdown of academic impact, for papers by Joseph Pierre Aboumsallem Breakdown of academic impact, for papers by Peter Groves Breakdown of academic impact, for papers by Nerea Hermida Breakdown of academic impact, for papers by Luigi Cavuto Breakdown of academic impact, for papers by Tadashi Kuroda
Rankless by CCL
2026